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We have studied a cohort of nemaline myopathy (NM) patients with mutations in the muscle a-skeletal actin
gene (ACTA1 ). Immunoblot analysis of patient muscle demonstrates increased g-filamin, myotilin, desmin
and a-actinin in many NM patients, consistent with accumulation of Z line-derived nemaline bodies. We
demonstrate that nebulin can appear abnormal secondary to a primary defect in actin, and show by isoelec-
tric focusing that mutant actin isoforms are present within insoluble actin filaments isolated from muscle
from two ACTA1 NM patients. Transfection of C2C12 myoblasts with mutant actinEGFP constructs resulted
in abnormal cytoplasmic and intranuclear actin aggregates. Intranuclear aggregates were observed with
V163L–, V163M– and R183G–actinEGFP constructs, and modeling shows these residues to be adjacent
to the nuclear export signal of actin. V163L and V163M actin mutants are known to cause intranuclear rod
myopathy, however, intranuclear bodies were not reported in patient R183G. Transfection studies in C2C12
myoblasts showed significant alterations in the ability of V136L and R183G actin mutants to polymerize and
contribute to insoluble actin filaments. Thus, we provide direct evidence for a dominant-negative effect of
mutant actin in NM. In vitro studies suggest that abnormal folding, altered polymerization and aggregation
of mutant actin isoforms are common properties of NM ACTA1 mutants. Some of these effects are
mutation-specific, and likely result in variations in the severity of muscle weakness seen in individual
patients. A combination of these effects contributes to the common pathological hallmarks of NM, namely
intranuclear and cytoplasmic rod formation, accumulation of thin filaments and myofibrillar disorganization.
INTRODUCTION
Nemaline myopathy (NM) is an inherited muscle disorder
characterized by muscle weakness and the presence of rod
bodies within the muscle fibers of affected patients. Clinically,
presentation of NM ranges from severe-congenital (lethal), to
milder childhood- or adult-onset forms. NM is genetically het-
erogenous, with disease-causing mutations identified in genes
encoding five different components of the thin filament.
Linkage analysis suggests that nebulin (NEB ) may be the
most common cause of NM (1). However, the nebulin gene is
large and highly repetitive and thus difficult to screen for
mutations. Consequently, nebulin mutations have been identified
in only a moderate number of patients to date (2–4). Mutations
in a-skeletal actin are the second most common cause of NM,
accounting for 20% of cases (5–7). Rare mutations have
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also been identified in a-tropomyosinslow (TPM3 ) (8–10),
b-tropomyosin (TPM2 ) (11) and troponin T1 (TNNT1 ) (12).
To date, 91 ACTA1 mutations have been identified, and are
distributed throughout the entire actin gene (6) (N.G. Laing,
unpublished data). Mutations in ACTA1 cause at least three
distinct pathological phenotypes: (1) cytoplasmic nemaline
bodies; (2) large myoplasmic accumulations of filamentous
actin; and (3) intranuclear rods.
The majority of actin NM cases result from dominant de novo
mutations. However, several families with autosomal dominant
actin NM (5,6,13), and rare cases of autosomal recessive NM
with compound heterozygous skeletal actin mutations have
also been described (6). A severe-lethal NM patient homozygous
for an actin nonsense mutation (R39X) has also been identified
(6,14). The patient was born to consanguineous parents who
were shown to be heterozygous for the actin null mutation
(N.G. Laing et al., unpublished data). These results indicate
that haploinsufficiency of actin does not underlie NM. This is
supported by transgenic mouse studies, which demonstrate the
heterozygote ACTA1 þ/2 mice have a normal lifespan and no
evidence of muscle weakness, whereas homozygous ACTA1
knock-out mice do not express any a-skeletal actin and die
from muscle weakness and starvation within 9 days after birth
(15). Similarly, homozygous expression of a null mutation
within the sarcomeric actin isoform (Act88F ) of Drosophila
indirect flight muscle results in a flightless phenotype and
severe sarcomeric abnormalities (16,17).
The fact that mutant actin isoforms produce dominant-
negative effects in yeast (18) and Drosophila (17,19), suggests
that a dominant-negative mode of disease pathogenesis is
likely in many NM patients with ACTA1 mutations. NM actin
mutations are likely to differentially affect specific actin-
binding interactions, and they may also invoke distinct
structural changes within the actin molecule or filament (6).
Nevertheless, multiple different actin mutations all result in
the same pathology of muscle weakness and nemaline rod
formation.
We have shown previously the abnormal localization of
other thin-filament proteins, such as tropomyosin and
nebulin, in patients with characterized ACTA1 mutations (5).
Therefore, this study sought to extend these observations
and examine the expression of a large panel of sarcomeric
and thin-filament proteins in our cohort of actin NM patients.
We sought to confirm the presence of mutant actin isoforms
within the sarcomeric and cytoskeletal actin filaments,
through isoelectric focusing, to confirm a dominant-negative
mode of disease pathogenesis. Furthermore, we have used
transfection studies in cultured myoblasts and myotubes to
examine abnormal aggregation of mutant actin isoforms, and
to demonstrate alterations in the equilibrium between filamen-
tous and soluble actin forms.
RESULTS
This study examines a series of 10 NM patients with
mutations in ACTA1 (Table 1). Patient T66I and patient
E72K are two new patients with ACTA1 mutations not pre-
viously described. Patient T66I was born at term with
severe hypotonia and minimal spontaneous movements of
the arms and legs. Although she could breathe independently,
she had difficulty with secretions and required a gastronomy
tube for feeding. The patient died of respiratory failure at
4.5 months of age. Gomori trichrome preparation of the
patient’s muscle biopsy shows numerous nemaline bodies
within most muscle fibers (Fig. 1A), but muscle of good overall
histology, with normal, well-packed fascicular bundles of
muscle fibers. Electron microscopy (EM) reveals nemaline
bodies (Fig. 1B) and accumulations of amorphous material
(Fig. 1C, arrowhead). The patient was found to have a
de novo missense mutation within ACTA1 not observed
in either parent, resulting in an amino acid substitution
of T66I (ACC! ATC).
Patient E72K is heterozygous for a de novo ACTA1 E72K sub-
stitution (GAG! AAG). She was born at 35 weeks gestation
with severe arthrogryposis and multiple contractures and frac-
tures. She had a high arched palate, pectus excavatum, poor
muscle development of the limbs, and died 2 h after birth from
respiratory failure. The autopsy report was unremarkable
except for analysis of the quadriceps muscle, which contained
numerous nemaline bodies, moderate variation in fibre size
and predominance of very small fibers. Examination of sections
of the psoas and the diaphragm showed myopathic changes but
did not show nemaline bodies. Gomori trichrome preparation of
autopsy samples from the patient’s quadriceps muscle shows
numerous nemaline bodies within most muscle fibers, poor
packing of muscle fibers and severely atrophied rod-containing
fibers (Fig. 1D). EM revealed severe sarcomeric disorganization
and the presence of nemaline bodies (Fig. 1E). EM analysis also
revealed cytoplasmic bodies (long arrowhead) and glycogen
accumulations (short arrowhead) (Fig. 1F).
Patient V163M has been briefly reported (6) and is
described here in more detail. She presented in the neonatal
period with severe weakness, and at 8 months of age req-
uired nasogastric feeding due to difficulties with swallowing.
At 3.5 years of age she was able to walk and swallow. Her
mother and grandfather had more mild facial and limb
muscle weakness, and also carry the V163M mutation.
Gomori trichrome staining of her muscle biopsy reveals
numerous intranuclear (IN) rods (Fig. 1G, arrowheads). EM
analysis defines more clearly the crystalline intranuclear
inclusions (Fig. 1H), and also reveals muscle fibers with
regions of amorphous material (Fig. 1I, long arrow) and
filamentous accumulations (Fig. 1I, short arrow and inset).
Similar IN rods and filamentous accumulations were
observed in the grandfather. However, filamentous accumu-
lations, but not IN rods, were evident in the biopsy specimen
obtained from the mother (data not shown). The absence of
detectable IN rods in the mother may reflect sampling, a
gene dosage effect, or variation in IN rod formation
between different muscles.
Immunostaining of muscle biopsy (rectus abdominus)
samples from patient T66I shows normal staining for actin,
nebulin and tropomyosin (Fig. 2D–F). Despite the extreme
myofibrillar disorganization within the muscle of patient
E72K, tropomyosin was present in all visible fibers, and exhib-
ited striated staining (Fig. 2I). In addition, a-actinin 2 posi-
tively labeled all fibers, and there was normal labeling for
myosin heavy-chain isoforms (slow, fast and developmental),
and members of the dystrophin complex (dystrophin,
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sarcoglycans and laminin a2) (data not shown). In contrast,
immunostaining for actin and nebulin demonstrated marked
abnormalities (Fig. 2G and H). Nebulin immunostaining was
performed using five different nebulin antibodies, all of
which showed very abnormal staining, with many negative
fibers (Fig. 2H). Consequently, a defect in the nebulin gene
was also considered as a potential disease candidate in this
patient. The identification of a primary abnormality within
ACTA1 emphasizes that nebulin can appear abnormal
secondarily to a primary defect in actin, a finding mirrored
in previous studies (5). Thus, nebulin abnormalities may be
a pathological consequence of primary actin mutations that
result in severe disruption of the sarcomeric thin filament,
and patients should be screened for mutations in ACTA1
before pursuit of nebulin as the disease candidate.
A mutation in a-skeletal actin affects expression of
other thin-filament proteins
We have characterized the expression of a panel of sarcomeric
and thin-filament proteins in eight NM patients with character-
ized mutations in a-skeletal actin (Fig. 3). For comparison, we
have also shown data from a NM patient with a mutation
in a-tropomyosinslow (TPM3, M9R) (Fig. 3A, lanes 7 and 8).
Muscle biopsy samples were separated into insoluble and
soluble protein pools using a buffer containing 0.5%
Triton X-100. Although separation of soluble versus insoluble
protein pools by this method is relatively crude, the insoluble
fraction represents proteins within the insoluble cytoskeleton
and sarcomeric apparatus. This fraction may also contain
proteins present within nemaline bodies. The soluble fraction
contains soluble proteins, or short filaments not sedimented
by centrifugation at 15 000g.
Solubilized muscle samples normalized for myosin content
were separated by gradient sodium dodecyl sulfate–polyacryl-
amide gel electrophoresis (SDS–PAGE), and PVDF mem-
branes were sectioned and probed with multiple antibodies.
Figure 3A represents data from patients with mild NM with
typical congenital- or childhood-onset forms of the disorder
(aged 5–46 years, see figure legends for details). Figure 3B
represents data from patients with severe congenital NM, all
of whom died within the first year of life (neonatal
samples). It is important to emphasize that these studies
represent analysis of a single biopsy specimen from affected
patients, and in one case the experiment could be repeated
only once (patient I357L), because of the scarcity of the
biopsy specimen available. Nevertheless, several trends were
observed. We detected a general increase in levels of
g-filamin, a-actinin, myotilin and desmin in many NM
patients, compared with unaffected age-matched controls
(Fig. 3A and B). These proteins are known to associate with
the Z-disc of muscle (20–25), thus elevated levels of these
proteins would be consistent with accumulation of Z line-
derived nemaline bodies within NM patient samples.
An additional tropomyosin band migrating above b-
tropomyosin was observed in patient G268C, and in the
adductor pollicis (TPMa), but not in the deltoid muscle
(TPMb) of the TPM3 (M9R) NM patient. This band likely cor-
responds to expression of another high molecular weight tro-
pomyosin isoform. The TM311 antibody used in this study
recognizes exon 1a of the TPM1 (alpha fast), TPM2 (beta)
and TPM3 (alpha slow) tropomyosin genes (26) contained
in all sarcomeric tropomyosins. However, exon 1a is also
expressed in smooth muscle (27) and fibroblast (28) high mol-
ecular weight tropomyosin isoforms (reviewed in 29). Patient
TPM has a primary mutation in a-tropomyosinslow (M9R), and
exhibits an altered ratio of a- and b-tropomyosin isoforms,
with increased levels of a-tropomyosinslow and reduced
levels of b-tropomyosin (30).
Higher levels of troponin Islow are seen in the soluble frac-
tion of NM muscle, relative to controls, and expression of
troponin Ifast closely parallels the fibre-type distribution
observed in these NM patients. Patients G268C, I136M,
N115Sa, N115Sb and TPM M9R have almost complete
Type 1 fibre predominance (5 and unpublished data) and
a virtual absence of immunoreactivity for troponin Ifast
(Fig. 3A). In contrast, patients R183G and NM2 both
possess 50% of fibers that stain positively for fast myosin,
and are also shown to express significant levels of troponin
Ifast by western analysis (Fig. 3B, lanes 5 and 6). For
patient T66I, the biopsy specimen taken at birth (39 weeks,
vastus lateralis) has 80% fast (and neonatal) myosin positive
fibers (data not shown) and also shows expression of troponin
Ifast (Fig. 3B, lane 3). In contrast, the biopsy specimen
taken at 10 weeks (rectus abdominus) displays virtually
complete Type 1 fibre predominance (data not shown), with
Table 1. Summary of ACTA1 nemaline myopathy patients
ACTA1 mutation NM classification Phenotype of actin–GFP fusion proteins in C2C12
1 T66I Severe congenital Similar to WT–actinEGFP
2 E72K Severe congenital Similar to WT–actinEGFP
3 N115Sa (13,5) Childhood onset Similar to WT–actinEGFP
4 N115Sb (13,5) Typical congenital
5 I136M (5) Typical congenital Cytoplasmic aggregates only
6 V163L (33) Severe congenital
Typical congenital
Predominantly intranuclear aggregates
Some cytoplasmic aggregates
7 V163M (6) Typical congenital Predominantly intranuclear aggregates
Some cytoplasmic aggregates
8 R183G (5) Severe congenital Intranuclear and cytoplasmic aggregates
Actin filament fragmentation
9 G268C (5) Childhood onset Similar to wild-type actinEGFP
10 I357L (5) Severe congenital Similar to wild-type actinEGFP
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no evidence for expression of troponin Ifast (Fig. 3B, lane 4).
Although it is tantalizing to infer that these findings may
reflect slow fibre conversion during the early postnatal
period for patient T66I, a direct comparison is not without
ambiguity, given the two biopsy samples are derived from
distinct sites.
Higher levels of cardiac actin were observed in several
severely affected NM neonates, compared with age-match
controls (Fig. 3B; compare patient samples in lanes 2–4 and
9, with age-matched controls in lanes 1 and 7). Cardiac
actin is expressed in human skeletal muscle during develop-
ment, and is down-regulated in the early postnatal period
(data not shown). Elevated levels of cardiac actin have also
been observed by immunostaining in severely affected NM
neonates (5 and data not shown), and may reflect altered matu-
ration or fibre regeneration in these patients. Immunoblot
analysis for a-skeletal actin shows broadly similar levels of
expression in both NM patients and controls, with the
exception of the NM disease control (Fig. 3B, lane 2, NM1),
for whom an ACTA1 mutation has been excluded, using the
standard ACTA1 mutation screen (5). Low levels of skeletal
actin relative to higher levels of cardiac actin were observed
in this patient (NM1). Multiple bands for a-skeletal actin
were observed in several severe lethal NM patients, and may
reflect increased degradation of actin in muscle of severely
affected patients.
Western analysis for nebulin is challenging, owing to its
extremely large size and insolubility. We observed variation
in levels of nebulin expression in control samples, despite
using an antibody recognizing the extreme N-terminus of
nebulin that is thought to be present in all isoforms (31).
Despite this variability, very low levels or absent nebulin
was observed in several NM patients. The very low or
absent nebulin signal persisted even with long exposures,
was evident in repeat experiments, and exceeded the normal
variation observed with control samples. In addition, nebulin
immunoreactivity was seen in the base of two wells loaded
with samples derived from two severely affected NM patients
[Fig. 3B, lanes 2 (NM1) and 10 (I357L)]. This pool of insolu-
ble or poorly solubilized nebulin may reflect the diseased state
of these muscle samples, which contained extremely high
levels of nemaline bodies within the muscle fibers.
Figure 1. Muscle histology in ACTA1 nemaline myopathy patients T66I, E72K and V163M. Gomori trichrome staining of frozen muscle sections shows
cytoplasmic nemaline bodies in patients T66I [(A) rectus abdominus, 400 magnification] and E72K [(D) quadriceps, 1000], and intranuclear rods in
patient V163M [(G) 1000] (arrows). Electron microcopy (EM) confirms the presence of nemaline bodies (arrowheads) in all three patients [(B) 25 000;
(E) 730; (H) magnification unavailable]. Accumulations of amorphous material (long arrows), devoid of sarcomeric register and organelles, were evident
in muscle fibers from patients T66I [C) 5000 and inset 17 000] and V163M [(I) magnification unavailable]. Accumulations of filamentous material were
a common feature in patient V163M, particularly in subsarcolemmal regions. (I) shows filamentous accumulations (short arrow) within a large region of amor-
phous material. A higher magnification image shows long filaments with partial striations [(I) inset, magnification unavailable]. Cytoplasmic bodies [(F) long
arrow] and glycogen accumulations [(F) short arrow] were a common feature in muscle from patient E72K.
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IEF shows mutant actin isoforms R183G and
E72K are expressed at significant levels within
muscle actin filaments
Missense mutations resulting in amino acid charge changes in
two of our severe actin NM patients were exploited to examine
levels of mutant and wild-type (WT) actin within muscle
biopsy specimens through isoelectric focusing (IEF) (Fig. 4). In
whole muscle lysates of control muscle, a major single spot cor-
responding to wild-type a-skeletal actin (predicted pI of 5.23) is
observed (Fig. 4A,WT). In contrast, two spots are clearly evident
for patients R183G and E72K. The R183G mutant actin (pre-
dicted pI of 5.16) is more acidic, and appears to be expressed
at roughly equal levels to wild-type actin (R183G, arrowhead).
In contrast, actin-E72K is more basic (predicted pI of 5.38) and
appears to be present at slightly reduced levels (E72K, arrow-
head), compared with wild-type actin.
To further explore the hypothesis of a dominant-negative
effect of mutant actin in NM, we sought to determine
whether mutant actin isoforms were correctly targeted to
the insoluble pool (the cytoskeletal and sarcomeric apparatus),
or were instead localized within the soluble protein fraction
(actin monomers and short actin filaments). Muscle samples
were extracted with 0.5% Triton X-100 buffer to separate
soluble and insoluble fractions. Proteins contained in each
fraction were denatured in IEF rehydration solution containing
8 M urea, 2% Triton X-100 and 36 mM dithiothreitol (DTT).
Relative levels of a-skeletal actin in each fraction were first
determined through western blot, so appropriate amounts of
each sample could be loaded onto IEF strips for analysis.
IEF analysis of soluble and insoluble protein (adjusted for
a-skeletal actin content) show a single spot for control
muscle, and two spots in both the insoluble and soluble
protein pools in patients R183G and E72K (Fig. 4B). Our
results demonstrate that mutant actin isoforms R183G and
E72K are expressed at significant levels within the pool of
insoluble actin filaments in these two patients. These studies
utilize an antibody that specifically recognizes alpha-skeletal
actin (32), which predominantly exists as sarcomeric actin
comprising the thin filament. Therefore, our results suggest
that the mutant actin isoforms are incorporated into sarcomeric
thin filaments, supporting the hypothesis that disease patho-
genesis in NM patients R183G and E72K results from a domi-
nant-negative (poison-protein) effect, rather than a shortage of
normal actin protein. However, the mutant actin isoform may
also be contained within cytoskeletal actin filaments or nema-
line bodies that do not comprise the sarcomeric thin filament.
a-Skeletal actin mutants form abnormal aggregates in
transfected C2C12 myoblasts
To examine the localization of mutant actin isoforms within
the actin cytoskeleton of C2C12 myoblasts, C-terminal
tagged actin–enhanced green fluorescent protein (EGFP)
Figure 2. Nebulin immunostaining may be abnormal in NM patients with a primary actin mutation. Immunohistochemical analysis of frozen muscle biopsy
sections from severe ACTA1 NM patients T66I and E27K, and an age-matched control. Muscle cryosections (8 mm) were stained with antibodies recog-
nizing sarcomeric actin (mAb 5C5, Sigma, recognizes a-skeletal and a-cardiac actin), nebulin (NB2) and sarcomeric tropomyosin (TM311), followed by a
CY3-conjugated secondary antibody. Actin, nebulin and tropomyosin showed normal homogenous labeling in control [(A–C) 400] and patient T66I
[(D–F, 400] muscle fibers. Despite the extreme diseased state of the muscle from patient E72K [(G–I) 1000], staining for (G) actin and (H) nebulin
was markedly abnormal, with many negative fibers (arrows), whereas tropomyosin staining was detected in all visible fibers (I). Images were captured using
an Olympus BX50 microscope linked to a SPOTTM digital imaging camera (Diagnostic Instruments Inc.) with Advanced V3.0.4 software, using 40
(UPlanFl 0.75) and 100 (UPlanFl 1.30 oil) lenses.
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fusion constructs were generated. Transfections with wild-type
actin–EGFP (WT-actinEGFP) into C2C12 myoblasts typically
produced stress-fibre or diffuse cytoplasmic staining (Fig. 5A).
In contrast, transfection of C2C12 myoblasts with several
mutant actin–EGFP constructs produced brightly fluorescent
actin–EGFP accumulations located within the cytoplasm
and nucleus of transfected cells (Fig. 5A). A summary of
actin aggregates formed by different mutant actinEGFP con-
structs is presented in Table 1.
Intranuclear actin aggregates were a striking feature of
V163L–actinEGFP and V163M–actinEGFP transfected C2C12
myoblasts (Fig. 5A, V163L, V163M), although cytoplasmic
aggregates were also observed in a subset of transfected
cells (data not shown). Only very low levels of cytoplasmic
or stress-fibre staining for transfected V163L–actinEGFP and
V163M–actinEGFP were detected. Intranuclear aggregates
were observed as either brightly fluorescent ‘oblong rods’
(Fig. 5A), or ‘star-like’ intranuclear bodies (Fig. 5B,i). The
V163L and V163M mutations have been identified in patients
with intranuclear rod myopathy, a phenotype which seems to
result specifically, but not exclusively, from mutation of
residue V163 (6,33,34). The oblong intranuclear aggregates
formed by V163L–actinEGFP and V163M–actinEGFP con-
structs in C2C12 myoblasts closely resemble intranuclear
bodies observed in muscle samples from patients with intra-
nuclear myopathy (Fig. 1G).
In this study, intranuclear actin accumulations were also
observed with a third construct, R183G–actinEGFP (Fig. 5A,
R183G). However, the R183G mutation was found in a
severe lethal NM patient (5) whose muscle biopsy did not
show intranuclear rods. Unlike V163L and V163M actin
mutants, significant levels of diffuse cytoplasmic staining,
with occasional labeling of stress fibers, were observed
in R183G–actinEGFP-transfected cells (Fig. 5A). Fragmenta-
tion of actin filaments, and large aggregates of cytoplasmic
actin were also features of a subset of actin–R183GEGFP trans-
fected cells (Fig. 5B,ii). Molecular modeling shows that amino
acid residues V163 and R183 are adjacent to the actin nuclear
export signal (NES) (35), lying within the 4 A˚ maximal radius
for bond formation (Fig. 8B). Therefore, V163L, V163M and
R183G actin mutations may affect the conformation or
binding properties of the NES, resulting in retention and
aggregation of these actin isoforms within the nucleus (see
Discussion).
The I136M–actinEGFP construct produced exclusively cyto-
plasmic accumulations, in only a subset of transfected cells.
The cytoplasmic localization of I136M–actinEGFP aggregates
is consistent with the pathology of patient I136M, which
shows only cytoplasmic nemaline bodies. I136M–actinEGFP
actin aggregates had a distinct morphology, typical of ‘a line
drawn by a highlighter pen’ (Fig. 5B,iii). Occasionally,
I136M–actinEGFP accumulations would also be ‘kinked’
(Fig. 5B,iii, inset). Transfection studies with several mutant
actinEGFP constructs (G268C, N115S, I357L, E72K, T66I)
did not produce actin aggregates, but resulted in normal
stress-fibre or diffuse cytoplasmic staining, similar to WT–
actinEGFP (data not shown). Very infrequently, rod-shaped
aggregates could be observed in one or two cells from cover-
slips transfected with WT-actin, and pathologically unremark-
able mutant actin constructs. Although rarely observed,
aggregation of WT–actinEGFP may represent a normal
response of cells to inappropriate folding or processing of
actin, that is exacerbated with particular actin mutations.
Phalloidin labeled the majority of mutant actinEGFP aggre-
gates (Fig. 5A, phalloidin), with the exception of I136M–
actinEGFP, for which no phalloidin labeling could be observed
(Fig. 5B, iv). I136M–actinEGFP aggregates also did not label
with DNase I (data not shown). Thus, I136M–actinEGFP
aggregates may indeed constitute filamentous actin, but
exhibit a tertiary conformation that is incompatible with phal-
loidin binding. Alternately, I136M–actinEGFP aggregates may
represent non-polymerized actin in a conformation incompati-
ble with DNase I binding.
To examine endogenous actin expression in transfected
cells, cells were labeled with antibodies recognising anti-
alpha skeletal actin (SKA-1) and anti-sarcomeric actin (5C5,
cardiac and skeletal actin isoforms) antibodies. Double-label-
ing with anti-alpha skeletal actin (SKA-1) and anti-sarcomeric
actin (5C5) weakly stained actin accumulations from I136M
and R183G actin constructs, but not the V163L and V163M
intranuclear aggregates (data not shown). These results
suggest that aggregates formed by the different mutant actin
constructs are not identical, and that antibody inaccessibility
due to steric hindrance needs to be considered when interpret-
ing co-labeling results.
To provide further evidence that the formation of actin
aggregates represents inherent misfolding of mutant actin and
is not a function of EGFP-fusion, we performed a control
study using an untagged V163L–actin construct. The V163L
mutation was selected, as virtually every myoblast transfected
with the V163L–actinEGFP construct displays intranuclear
actin aggregates, and these aggregates may be co-labeled
by phalloidin. Analysis of C2C12 myoblasts transfected with
an untagged V163L-actin construct clearly demonstrates
Figure 3. Western analysis of sarcomeric protein expression in nemaline myopathy. Immunoblot analysis of (A) mild and (B) severe ACTA1 NM patients.
Frozen muscle biopsy sections were fractionated into insoluble and soluble protein pools. Solublized lysates were separated by SDS–PAGE using 3–12% poly-
acrylamide gradient gels, and transferred to PVDF membranes. There is an increase in levels of gamma-filamin, alpha-actinin, myotilin and desmin in many NM
patients. Nebulin expression is secondarily reduced in some NM patients with a primary abnormality in ACTA1 [(3A) lane 6; (3B) lanes 2,5,6,9,10]. Control
muscle specimens were histologically normal and obtained from individuals with no history of neuromuscular disease. y ¼ years, wks ¼ weeks. (A) Lane 1,
control 1 (quadriceps, 28y); Lane 2, control 2 (quadriceps, 5y); Lane 3, patient G268C (unknown site, 5y); Lane 4, patient I136M (deltoid, 28y); Lane 5,
patient N115Sa (quadriceps, 17y); Lane 6, patient N115Sb (quadriceps, 36y); Lane 7, patient TPMa (TPM3 M9R mutation) (adductor pollicis, 46y); Lane 8,
TPMb (deltoid, 46y); Lane 9, control 3 (deltoid, 38y). Patient N115Sa is the daughter of patient N115Sb. TPMa and TPMb represent two separate muscle
samples derived from the same patient at the time of autopsy. (B) Lanes 1 and 8, control 1 (psoas, 36/40 wks); Lane 2, NM1 (quadriceps, 36/40 wks); Lane
3, patient T66Ia (vastus lateralis, 39/40 wks); Lane 4, patient T66Ib (rectus abdominus, 10 wks); Lane 5, patient R183G (quadriceps, 7 wks); Lane 6, NM2
(deltoid, 8 wks); Lanes 7 and 11, control 2 (unknown site, 26 days); Lane 9, patient E72K (quadriceps, 35/40 wks); Lane 10, patient I357 (vastus lateralis,
5 wks). T66Ia and T66Ib represent two muscle samples from the same patient, obtained in separate biopsy operations at different ages.
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intranuclear actin aggregates, identified through phalloidin
staining (Fig. 5B,vi). No evidence of phalloidin-labeled
intranuclear actin aggregates was observed using an untagged
wild-type actin construct (data not shown). Additionally,
we performed co-transfection studies combining V163L–
actinEGFP, together with WT actin fused to the red fluorescent
protein DsRED (pDsRed2-N1, BD Biosciences Clontech),
and showed that WT-actindsRED did not localize to the actin
aggregates (data not shown).
To determine that C-terminal EGFP tagging of a-skeletal
actin did not impair its normal polymerization and incorpor-
ation into sarcomeric thin filaments, we differentiated myo-
blasts transfected with WT-actinEGFP. Upon differentiation,
striated staining for WT-actinEGFP was observed in a subset
of myotubes, and demonstrates that actinEGFP conjugates can
correctly localize within the sarcomeric thin filament
(Fig. 5B,viii). The ability of mutant actin isoforms to contrib-
ute to the sarcomeric thin filament is now the subject of further
studies within our laboratory.
Mutations in a-skeletal actin differentially affect poly-
merization and incorporation into actin filaments
We examined the ability of several actin isoforms to polymerize
and incorporate into the filamentous cytoskeleton of transfected
C2C12 myoblasts and differentiated myotubes. C2C12 myo-
blasts were transfected with C-terminal Flag-tagged mutant
actin constructs (WT, I136M, V163L, R183G, C268G and
I357L), trypsinized and re-plated onto feeder layers of confluent
cartilage fibroblasts. Fibroblast feeder layers prolong the life-
time of spontaneously contracting cultured myotubes, permit-
ting a greater degree of sarcomeric maturity (36). Duplicate
wells were harvested 1 day after replating (D0) and after 3
(D3) and 6 days (D6) of differentiation. Typically, C2C12
cultures would be twitching on D3, and contracting more vigor-
ously on D6, reflecting more advanced sarcomeric development
at later differentiation time-points. Figure 6B shows relative
levels of actinFLAG present in the insoluble and soluble protein
pools at the three different time-points. The insoluble fraction is
enriched for actinFLAG contained within large cytoskeletal and
sarcomeric actin filaments, and will also include actin aggre-
gates. The soluble protein pool contains soluble actinFLAG
monomers, and short actin filaments not sedimented by cen-
trifugation at 15 000g.
In undifferentiated myoblasts (D0), wild-type actin was
present at roughly equal levels in soluble (48% total actin)
and insoluble (52% total actin) fractions. As C2C12 myotubes
differentiated, there was a concomitant increase in levels of
insoluble actin, reaching 76%of total actin levels byD6 (Fig. 6).
I136M–actinFLAG, G268C–actinFLAG and I357L–actinFLAG
constructs behaved similarly to WT-actinFLAG (Fig. 6), with
approximately half of the expressed actin detected within the
insoluble cytoskeleton at D0, increasing to 69–76% by D6. In
contrast, R183–actinFLAG contributed less efficiently to insolu-
ble actin filaments, localizing predominantly to the soluble
protein fraction (70% total actin) in undifferentiated myo-
blasts (D0) (H0:T= t, P  0.001) and early myotubes (D3)
(H0:T= t, P  0.001), with gradual incorporation into insolu-
ble actin filaments (53% total actin) in more mature myotubes
(D6) (H0:T= t, P  0.004). These results suggest an impaired
ability of R183-actinFLAG to contribute to long, insoluble actin
filaments, either in conjunction with cytoplasmic actin isoforms
that predominate in undifferentiated myoblasts, or with sarco-
meric actin isoforms that predominate in differentiated myo-
tubes (36, data not shown).
In contrast, V163L–actinFLAG exhibited near-maximal
levels of insoluble actin at D0 (68% total actin) (H0:T= t,
P  0.024), suggesting enhanced polymerization of V163L–
actinFLAG with cytoplasmic actin isoforms expressed in undif-
ferentiated myoblasts. However, levels of insoluble actin
remained fairly constant with differentiation, and did not
differ significantly from WT–actinFLAG at D3 or D6 (Fig. 6).
A predisposition of V163L–actinFLAG for forming insoluble
actin filaments is consistent with our immunocytochemical
findings for V163L–actinGFP, which forms filamentous intra-
nuclear actin aggregates (Fig. 5). These results are also con-
sistent with the pathology of patient V163L, who shows
intranuclear rod bodies, and for whom large intracellular
accumulations of filamentous actin were a striking feature.
Figure 4. Isoelectric focusing of NM muscle samples supports the hypothesis
of a dominant-negative ‘poison-protein’ effect. IEF of patients R183G and
E72K from frozen muscle biopsies using (A) whole muscle lysates and (B)
extraction of muscle into insoluble and soluble protein pools. The PVDF mem-
branes were probed with an alpha-skeletal actin-specific antibody (SKA-1)
(1:300 dilution). A single spot corresponding to wild-type (WT) alpha-skeletal
actin is evident in the age-matched control sample (predicted pI of 5.23). In
contrast, two spots are clearly evident for patients R183G and E72K. The
R183G mutant actin (predicted pI of 5.16) is slightly more acidic and is
expressed at roughly equal levels (R183G, arrowhead) to WT actin. E72K is
more basic (predicted pI of 5.38) and is expressed at lower levels (E72K,
arrowhead) compared with WT. Both mutant actin isoforms, R183G and
E72K, localize to the insoluble protein pool in significant quantities,
suggesting that they both contribute to the sarcomeric thin filaments, support-
ing a dominant-negative (poison-protein) effect rather than haploinsufficiency
(shortage of normal actin protein).
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Figure 5. Nemaline myopathy actin mutants form abnormal aggregates in cultured C2C12 myoblasts. C2C12 myoblasts were transfected with EGFP-tagged
actin constructs and stained with TRITC-phalloidin (red) and emerin (blue), labeled with a CY5-conjugated secondary antibody, to highlight cell nuclei.
(A) EGFP fluorescence (left panel) shows diffuse cytoplasmic staining or stress-fibre staining for WT-actinEGFP. In contrast, intranuclear rod-shaped aggregates
were observed with V163M–actinEGFP, V163L–actinEGFP and R183G–actinEGFP constructs. Note the very low levels of cytoplasmic staining with V163M–
actinEGFP and V163L–actinEGFP constructs, compared with R183G–actinEGFP for which cytoplasmic and stress-fibre staining is clearly shown. Phalloidin
co-labels actin aggregates formed by V163M–, V163L– and R183G–EGFP-tagged actin constructs [(A) middle panel, arrowheads]. (B) In addition to rod-
shaped actin aggregates, star-like intranuclear aggregates were detected in a subset of cells transfected with V163L–actinEGFP (i) and V163M–actinEGFP
(data not shown). (ii) Fragmentation of cytoskeletal actin filaments and cytoplasmic aggregates were a feature of a subset of cells transfected with R183G–
actinEGFP. (iii–v) I136M–actinEGFP produces cytoplasmic actin aggregates that do not label with phalloidin. (vi and vii) Intranuclear aggregates labelled by
phalloidin are detected in C2C12 myoblasts transfected with untagged V163L–actin (arrowheads), demonstrating intranuclear actin aggregation is an inherent
property of this actin mutation, and does not result from EGFP-tagging. (viii) Differentiation studies show that EGFP-tagged WT actin localizes normally to the
sarcomeric thin filament. Confocal microscopy was performed using a Leica SP2 Scanning Laser Confocal Microscope using a 100 (HCX PL APO 1.40) oil
lens with 1.84–3.5 zoom.
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A conservative amino acid substitution (I357L) within
a-skeletal actin results in conformational changes
detected by native PAGE
Thus far, all studies examining the properties of a mutant actin
isoform found in one severely affected NM patient showed no
significant differences to wild-type actin (patient I357L). The
amino acid substitution in this patient is very conservative,
isoleucine 357 to leucine, but results in a lethal phenotype.
Molecular modeling of this mutation highlights potential
alterations in hydrogen bonding at the extreme C-terminus
of G-actin (Fig. 8). Therefore, native polyacrylamide
electrophoresis was used to explore whether altered mobility
of I357L–actin could be observed.
Expression constructs containing cDNA sequences for WT
actin, I357L and R183G were generated (actin sequence
only, no EGFP or FLAG tag). 3T3 fibroblasts were trans-
fected, and soluble actin was derived using ‘G-actin’ buffer
(see Materials and Methods). PVDF membranes probed
with anti-sarcomeric actin demonstrate the slightly slower
mobility of I357L–actin (Fig. 7). Although subtle, this slight
retardation in the native mobility of I357L–actin was repeated
Figure 5. Continued.
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on four separate occasions, and suggests a less compact three
dimensional conformation of the actin monomer.
DISCUSSION
To date, 91 mutations in ACTA1 have been identified in
patients with NM and related disorders, including actinopathy
and intranuclear rod myopathy. Our previous study has shown
that the incidence of ACTA1 mutations in idiopathic NM is
roughly 20%, although the incidence of actin mutations
within the subset of patients with severe-lethal congenital
NM patients may be as high as 50% (5–7,13). This study
examined a series of 10 NM patients with mutations in
ACTA1, eight of whom have been described previously
(5,6,13,33), and two new patients possessing novel ACTA1
mutations (patients T661 and E72K).
The filamentous accumulations observed within the muscle
fibers of patient V163M (Fig. 1I) are similar to the accumu-
lations of filamentous actin previously described in three
ACTA1 NM patients (13,33). This may be a pathological
feature common to patients with mutations in ACTA1, and
may help direct mutational analysis (6). For patient E72K,
muscle samples from three sites were examined at autopsy,
although nemaline bodies were identified only in the
quadriceps, not the psoas or diaphragm. This finding is sup-
ported by previous studies of NM patients in whom rods
were not identified in some muscles (37–39) and highlights
the importance of analysis of muscle samples from multiple
sites for accurate diagnosis of NM.
Nebulin expression was markedly reduced in patient E72K,
by immunostaining and western analysis (Figs 2 and 3B). Our
laboratory has screened 23 idiopathic NM patients for nebulin
expression, using a panel of five nebulin antibodies, and patient
E72K exhibited the most striking abnormality observed to
date (A. Domazetovska, unpublished data). Consequently, a
defect in the nebulin gene was first considered as the potential
disease candidate in this patient, and the identification of a
primary mutation in ACTA1 was a surprising but clinically
important finding, with significant impact on genetic counsel-
ing for the patient’s family. We have previously described
nebulin abnormalities in two additional severe congenital
ACTA1 NM patients [R183G and I357L (5)]. These results
show that protein analyses may not accurately guide mutation
analysis and advocate screening of the ACTA1 gene prior to
pursuit of other disease candidates.
The reason for nebulin abnormalities in ACTA1 NM patients
is unclear, but is more common in severely affected patients
and is more marked than observed abnormalities in other
thin-filament proteins, such as tropomyosin. Although purely
speculative, perhaps the low, absent or variable levels of
nebulin within individual fibers of severely affected NM
patients may reflect instability and increased turnover of the
thin filament, whereby synthesis of the extremely large
nebulin protein is unable to keep up with turnover.
Analysis of sarcomeric protein expression revealed that
g-filamin, a-actinin, myotilin and desmin are upregulated in
many NM patients, compared with unaffected age-matched
controls. This may be due to the association of these proteins
with the Z-disc, and their localization within nemaline bodies.
However, effects relating to changes in fiber-type, compo-
sition or from regeneration cannot be excluded. a-Actinin 2
and myotilin have been shown to be components of nemaline
bodies (40–42). There is some evidence for desmin expression
Figure 6.Mutations in a-skeletal actin differentially affect polymerization and incorporation into actin filaments in cultured C2C12 myotubes. C2C12 myoblasts
transfected with FLAG-tagged actin constructs were harvested 24 h after replating (D0, myoblasts), and after 3 days (D3, immature myotubes) and 6 days (D6,
more mature myotubes) of differentiation. Each sample was separated into insoluble (filled bars) and soluble (hatched bars) protein pools, using a buffer contain-
ing 0.5% Triton X-100. Solubilized lysates were separated by SDS–PAGE and transferred to PVDF membranes. Levels of actinFLAG contained within each
protein pool was determined using an anti-FLAG antibody. Band intensity was quantified through densitometric analysis. The mean data from multiple exper-
iments is shown in (A). WT, n ¼ 10; V163L, n ¼ 4; R183G, n ¼ 5; I136M, n ¼ 4; G268C, n ¼ 4; I357L, n ¼ 6. The comparison of means was performed using
a Mann–Whitney non-parametric test. (B) Western analysis showing levels of actinFLAG within the insoluble (Insol) and soluble (Sol) protein pools. The results
shown are data from a single experiment for each actinFLAG construct, at the three different time-points following transfection (D0, D3, D6).
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within nemaline bodies (43,44), and we have observed posi-
tive staining for filamin within nemaline bodies of a subset
of NM patients (unpublished data). Filamin showed variable
localization to either the insoluble or soluble pool in control
samples (Fig. 3B, compare lanes 1 and 7), although the signifi-
cance of this finding is unknown. Studies have shown that
filamin has dual localization both at the Z-line and at the
subsarcolemmal cytoskeleton (20,21). Our results may reflect
variation in tethering at these sites, and thus sensitivity to
0.5% Triton X-100.
IEF demonstrates that mutant actin isoforms, R183G and
E72K, are present at significant levels within the skeletal
muscle of the affected patient. We also demonstrate that the
mutant actin isoforms contribute to the insoluble protein
pool, comprising the insoluble cytoskeleton and sarcomeric
apparatus. Because the majority of a-skeletal actin found in
muscle comprises the sarcomeric thin filament, our results
imply that a significant portion of the mutant actin isoform
is present within the sarcomeric thin filament, suggesting a
dominant-negative mode of disease pathogenesis. However,
the mutant actin isoforms may also be contained in nemaline
bodies or actin aggregates. For patients where large regions
of their muscle fibers are occupied by nemaline bodies or fila-
mentous aggregates of actin, we cannot exclude the possibility
that a shortage of functionally normal actin able to contribute
to sarcomeric thin filaments also contributes to disease
pathogenesis.
The recent identification of a severe NM patient homozy-
gous for a nonsense mutation in ACTA1 (14), born to pheno-
typically normal consanguineous parents (N.G. Laing et al.,
unpublished data), implies that possession of a single func-
tional actin allele is sufficient for normal muscle function. A
dominant-negative mode of disease pathogenesis in ACTA1
NM is supported by studies in the KM88 (null mutation of
the muscle-specific actin gene Act88F ) Drosophila flightless
mutant, expressing no sarcomeric actin within the flight
muscle (45). P-element transformation of a panel of mutant
actin isoforms demonstrated a clear gene-dosage effect that
was mutation specific (17). Transformation of KM88 flies
with WT actin restored almost normal flight ability.
Expression of a panel of actin mutants as a 1:1 ratio with
WT actin resulted in a gradient of effects, from moderate
impairment in flight ability to a completely flightless pheno-
type. In some cases, a flighted phenotype could be restored,
or partially restored, using a lower ratio of mutant :WT actin
(1:2), but restoration of flight ability by this means was
mutation-dependent, with maintenance of a flightless pheno-
type for a subset of more severe actin mutants (17).
Expression of EGFP-tagged mutant actin constructs in C2C12
myoblasts demonstrates abnormal aggregation of several
mutant actin isoforms into ‘rod-shaped’ actin accumulations.
Intranuclear accumulations resulted from transfection of
V163L–actinEGFP, V163M–actinEGFP and R183G–actinEGFP
constructs. V163L–actinEGFP and V163M–actinEGFP constructs
were modeled on patients with intranuclear rod myopathy,
whereas R183G–actinEGFP is modeled on a patient whose
biopsy showed no evidence of intranuclear rods, although this
may reflect the limited sampling associated with EM analysis.
Only cytoplasmic actin accumulations were evident with the
I136M–actinEGFP construct. This observation is consistent
with the pathology of the patient’s muscle (patient I136M),
which contains numerous nemaline bodies located exclusively
within the cytoplasm (5). Other mutant actinEGFP constructs
(T66I, E72K, N115S, G268C and I357L) did not induce actin
accumulations in C2C12 myoblasts, and future experiments
will now focus on the contribution of these mutant actin iso-
forms to the sarcomeric thin filament.
Actin has two NESs thought to govern the active transport of
actin from the nucleus in into the cytoplasm mammalian cells
(35). Disruption of conserved residues within the actin NES
results in retention of actin within the nucleus (35). Molecular
modeling shows the proximity of residues V163 and R183
to amino acids within the actin NES, located within the 4 A˚
maximal radius for bond formation. The intranuclear actin aggre-
gates we observe in C2C12 myoblasts transfected with V163L–
actinEGFP, V163M–actinEGFP and R183G–actinEGFP constructs
bear striking resemblance to intranuclear ‘paracrystal structures’
reported by Wada et al. (35), following treatment of murine
fibroblasts with leptomycin B, a nuclear export inhibitor. Thus,
our results suggest that NM mutations V163L, V163M and
R183G may induce steric or conformational changes of the
NES, perhaps affecting the binding of effector molecules to
this region, contributing to the nuclear retention and aggregation
of these mutant actin isoforms.
Our study employed the intracellular environment of
differentiating C2C12 myoblasts to examine the ability
of NM mutant actin isoforms to polymerize with endogenous
actin isoforms, and contribute to the insoluble cytoskeleton
and developing sarcomeric apparatus. R183G–actinFLAG
showed a reduced ability to incorporate into insoluble actin
filaments, compared with WT–actinFLAG, producing high
levels of soluble actin (actin monomers or short filaments
not pelleted by 15 000g ). These alterations in polymerization
capacity were highly significant (Fig. 6A). The R183 amino
acid residue lies near to the ATP-binding site of actin
(Fig. 8). Alterations in ATP binding would likely affect
actin polymerization, and several ACTA1 NM mutations
cluster to this region (6). Although R183 is not predicted
Figure 7. A conservative amino acid substitution (I357L) within alpha-skel-
etal actin results in conformational changes detected by native PAGE.
NIH3T3 cells were transfected with untagged wild-type (WT) actin, and
untagged mutant actin constructs R183G and I357L. Cells were harvested,
extracted for soluble actin protein and separated by non-denaturing electro-
phoresis using a 5–12% gradient gel. The blot was probed with a sarcomeric
actin-specific antibody (5C5, Sigma) and the bands shown are the only bands
visible on the blot. Under these conditions, the I357L mutant actin protein runs
slightly slower than WT actin. This subtle shift in mobility was repeated on
four separate occasions, and suggests an altered tertiary conformation of this
actin monomer. Control (Con) represents untransfected NIH3T3 cells.
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to form bonds with ATP directly, it does interact with two
residues that are thought to mediate ATP-binding (S14
and D157) (46–48). Residue S14 has crucial role in ATP-
binding, and mutation of this residue to glycine or cysteine
results in a lethal phenotype in yeast (48). Polymerization of
actin is a major ATP-consuming reaction, and depletion
of intracellular ATP levels has been shown to produce
cytoplasmic actin aggregates in cultured rat neurons (49,50).
Thus, whether actin aggregates observed following trans-
fection of V163L, V163M, R183G and I136M EGFP-tagged
mutants relates to intracellular levels of ATP merits further
investigation.
Alterations in polymerization of NM ACTA1 mutants
are complemented by a recent study showing increased
levels of short-actin filaments (not pelleted by centrifugation
at 400 000 g ) following in vitro polymerization of skeletal
actin purified from muscle from a NM ACTA1 patient
possessing a M132V missense mutation (51). Similarly,
analysis of a large panel of NM ACTA1 mutants found
impaired polymerization of several mutant actin isoforms,
using in vitro translation assays, and sedimentation with
carrier actin (52). Moreover, the authors also demonstrate
increased association of mutant actin isoforms with chaperone
proteins, using in vitro binding assays, and also document
abnormal aggregation of mutant actin protein products in
non-muscle cells (52).
In contrast, V163L–actinFLAG exhibited maximal levels of
insoluble actin filaments immediately following transfection,
exceeding levels observed with WT–actinFLAG. An enhanced
capacity of V163L–actinFLAG to form insoluble actin
species is supported by our immunohistochemical findings
in V163L–actinEGFP-transfected C2C12 myoblasts, where
brightly fluorescent filamentous actin aggregates are the only
discernible feature, with low or undetectable levels of cyto-
plasmic or stress-fibre staining. These findings also compare
with the pathology of patient V163L, who shows intranuclear
rod bodies, and for whom large intracellular accumulations of
filamentous actin were a striking feature. Our molecular mod-
eling shows that V163 lies within 4 A˚ of residues A170 and
I175 of NES1. I175 is one of the four critical hydrophobic
residues found in all NES sequences shown to be important
for functional nuclear export (35). A170 lies outside the
maximal 4 A˚ radius for bond formation following substitution
of V163 for L163. Sparrow et al. (6) also note that substitution
of leucine for valine at position 163 may result in distortion of
the actin hinge region, thought to be important for ATP
binding and exchange, and integral to actin filament formation
and stability.
In summary, our studies provide a number of insights into
the pathogenetic mechanisms of ACTA1 NM. We provide,
for the first time, direct evidence for a dominant-negative
effect of mutant actin isoforms in NM. Our results show that
mutant actin is present in patient skeletal muscle and is
likely incorporated into the sarcomeric thin filament. In vitro
studies demonstrate that formation of actin aggregates within
the cytoplasm and nucleus, altered polymerization and abnor-
mal folding are the properties of NM ACTA1 mutants. Some of
these effects are mutation-specific, reflecting involvement of
different functional domains of the actin molecule, and likely
resulting in variations in the severity of muscle weakness
seen in individual patients. A combination of these effects
contributes to the common pathological hallmarks of NM,
namely intranuclear and cytoplasmic rod formation, accumu-
lation of thin filaments and myofibrillar disorganization.
MATERIALS AND METHODS
Patients
This study examines a series of 10 NM patients with mutations
in ACTA1 (Table 1). Patients N115Sa, N115Sb, I136M,
R183G, G268C and I357L have been described in an earlier
report (5). Patient V163L, with actin accumulations and intra-
nuclear myopathy has been described previously (13,33).
Patient V163M, with almost exclusive intranuclear rod myo-
pathy has also been briefly reported (6) and is reported here
in more detail. Patients T66I and E72K represent two new
patients with ACTA1 mutations not previously described. For
comparison, muscle tissue was also studied from a NM
patient with a missense mutation in TPM3 (M9R) (8), and
from two severe-congenital NM patients (patients NM1 and
NM2) in whom the primary disease-causing mutation is
unknown (routine ACTA1 screening did not identify a
mutation). Control samples were from patients with no form
of neuromuscular disease and with normal muscle histology.
Patients TPM, E72K, control 1 (36/40 week, psoas muscle,
Fig. 3B) and control 2 (26 days, unknown site, Fig. 3B)
were obtained at autopsy. Control 2 (quadriceps, 5 year,
Fig. 3A) was obtained from a leg amputee. The remaining
muscle samples were obtained at biopsy.
Constructs
All molecular biology reagents were obtained from Roche,
unless otherwise specified. Primers were generated by Life
Technologies or SigmaGenosys. All actin constructs were
generated in the pEGFP-N1 backbone (Clontech). WT–actinEGFP
was generated through amplification of a-skeletal actin from
skeletal muscle-specific cDNA (forward primer 50gatctcgag
atgtgcgacgaagacgag30; reverse primer 50gcagaattcggaagcatttg
cggtggacg30) introducing XhoI (50) and EcoRI (30) restriction
sites. Polymerase chain reaction products were gel purified
(JETquick Gel Extraction spin kit, Genomed), and subcloned
into the XhoI and EcoRI sites of the pEGFP-N1. EGFP-
tagged actin mutants were generated through site-directed
mutagenesis (QuickChangewSite-Directed Mutagenesis kit,
Stratagene). To generate FLAG-tagged constructs, the EGFP
cDNA was excised from WT-actinEGFP with EcoRI and NotI
and the FLAG sequence was replaced using two annealed
oligos (50aattctggactacaaggacgacgatgacaagtagc30; 50ggccg
ctacttgtcatcgtcgtccttgtagtccag30) to generate pActinFLAG.
Mutant actin cDNAs were excised from the actin–EGFP con-
structs, using Xho I (50) and EcoRI (30), and subcloned into
the same sites of pActinFLAG.
Cell culture
All tissue culture media and reagents were purchased from
Invitrogen unless otherwise specified. The isolate of C2C12
myoblasts (P21) used in this study forms spontaneously
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contractile myotubes, and were a gift from Dr Edna Hardeman,
Children’s Medical Research Institute, Sydney. Cultures of
neonatal human cartilage fibroblasts were provided by the
Cytogenetics Department, Children’s Hospital at Westmead,
and de-identified in accordance with Children’s Hospital at
Westmead ethical guidelines. C2C12/fibroblast co-cultures
were generated as described previously (36).
Transfections
C2C12 or NIH3T3 cells were trypsinized and plated 1 day
prior to transfection, in growth media without antibiotics.
The cells were transfected at 90% confluence using Lipofecta-
mine2000TM, according to the manufacturer’s instructions.
Briefly, per 2 cm2 culture area, 1.2 mg of DNA and 3.6 ml
Figure 8. Molecular modeling of ACTA1 mutants I357L, R183G and V163L. (A) I357 resides at the C-terminus of actin (I357, red). Amino acid side chains
within a 4 A˚ radius (the maximal distance for predicted bond formation) are shown in yellow. Predicted hydrogen bonding is shown as dashed lines (black, strong
H-bonds; grey, weak H-bonds). Substitution of I357 to L357 (L357, red) predicts alterations in amino acid side chains within a 4 A˚ radius, and alterations in
predicted hydrogen bonding within this C-terminal region. (B) Molecular modeling of actin residues R183 and V163 (R183 and V163, red) shows they are
located near the nuclear export sequence 1 (NES1) of actin (35) (NES shown in blue). R183 lies within 4 A˚ of residue A181 located within NES1, and also
resides adjacent to the ATP-binding site (ATP molecule shown in brown). Substitution of R183 to G183 (G183, red) alters the predicted amino acid side
chains within a 4 A˚ radius and also alters predicted hydrogen bonding within the region. V163 lies within 4 A˚ of residues A170 and I175 of NES1. I175 is
one of the four critical hydrophobic residues found in all NES sequences shown to be important for functional nuclear export (35). A170 lies outside the
maximal 4 A˚ radius for bond formation following substitution of V163 for L163 (L163, red). Images were generated using DeepView/Swiss-Pdb Viewer
(v3.7). http://www.expasy.org/spdbv/. The orientation of the L357, G183 and L163 substitutions were predicted by the Swiss-Pdb viewer software and are
based on lowest predicted net energy.
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lipid were prepared in 0.1 ml of OptimemTM and incubated in
0.4 ml of growth media without antibiotics. Cells were trans-
fected overnight, washed twice with phosphate buffered
saline (PBS) and replenished with growth media. For polym-
erization studies, C2C12 cells were trypsinized after overnight
transfection, and seeded in normal growth media onto conflu-
ent fibroblast monolayers prepared in 12-well plates. D0 cells
were harvested the next day. The remaining cells were incu-
bated in differentiation media, and D3 and D6 cells were har-
vested after 3 days and 6 days of differentiation, respectively.
Immunohistochemistry
Transfected C2C12 cells grown on thermonox coverslips
(Nunc) were fixed and permeabilized in PBS containing 3%
paraformaldehyde and 0.1% Triton-X 100 for 10–15 min at
room temperature (RT). Samples were washed three times in
PBS, then incubated in blocking buffer (PBS plus 2%
bovine serum albumin) for 15 min at RT. Coverslips were
incubated with a monoclonal antibody (mAb) that recognizes
emerin (NCL-emerin, 1:100) (Novacastra Laboratories Ltd)
diluted in blocking buffer for 1–2 h at RT. After washing,
coverslips were blocked as mentioned earlier and then incu-
bated with CY5-conjugated donkey anti-mouse IgG (1:200)
(Jackson ImmunoResearch Laboratories. Inc.), together with
TRITC–phalloidin (1:200) (Sigma) for 1 h at RT. Samples
were washed three times in PBS and mounted on
22  50 mm2 glass coverslips using FluorsaveTM mounting
reagent (Calbiochem). Confocal microscopy was performed
using a Leica SP2 Scanning Laser Confocal Microscope.
Autofluorescence of the thermanox coverslips was overcome
by imaging through the glass coverslip. A droplet of oil was
applied to the base of the thermanox coverslip and placed
onto a glass slide (held in position by the oil), leaving the
glass coverslip uppermost. All imaging was performed using
sequential scanning, with restricted emission spectra shown
to detect only the fluorophor of interest.
Antibodies
Antibodies used for western blotting; sarcomeric actin (5C5)
(1:2000), sarcomeric tropomyosin (TM311) (1:30, 000),
nebulin (NB2) (1:750) and anti-FLAGw M2 (1:5000) were
obtained fromSigma.Anti-cardiac actin (1:1000)was purchased
from American Research Products. mAbs that recognize desmin
(NCL-DES) (1:500) andmyotilin (NCL-MYOT) (1:2000) were
purchased from Novacastra Laboratories Ltd. Troponin Tslow
(CT3) (1:50), Troponin Ifast (MynT-fast) (1:400), and Troponin
Islow (MynT-slow) (1:1500) mAbs were obtained from the Uni-
versity of Iowa hybridoma bank. A polyclonal antibody (pAb)
that recognizes a-actinin-2 (4B2) (1:60, 000) was kindly pro-
vided by Dr Alan Beggs (Harvard Medical School, Boston).
The pAb filamin (FLN) (1:2500) was kindly provided by Prof
Lou Kunkle (Harvard Medical School, Boston). A pAb that
specifically recognizes a-skeletal actin (SKA1) (1:300) was
made by Dr Sophie Clement (University of Geneva). Horse
radish peroxidase-conjugated sheep anti-mouse (1:3000) and
donkey anti-rabbit IgG (1:3000) antibodies were obtained
from Amersham Biosciences.
Extraction of insoluble and soluble protein pools
Muscle samples. One 8 mm frozen muscle biopsy section,
measuring roughly 10 mm2, was suspended in 20 ml lysis
buffer [LB; 50 mM MES pH 6.8, 1 mM EGTA pH 8.0,
50 mM KCl, 1 mM MgCl2, 0.5% Triton X-100, (53)]. A pro-
tease inhibitor (PI) cocktail from Sigma was added immedi-
ately prior to use (1:500). Samples were incubated on ice
for 15 min, then centrifuged at 15 000 g for 30 min at 48C.
The supernatant (soluble fraction) was removed and mixed
with 4 SDS sample buffer [250 mM Tris pH 8.8, 8% SDS,
40% glycerol, 200 mM DTT, PI cocktail (1:125), bromophe-
nol blue (BPB)]. The pellet (insoluble fraction) was resus-
pended in 1 SDS sample buffer [62.5 mM Tris pH 8.8, 6%
SDS, 10% glycerol, 50 mM DTT, PI cocktail (1:500), BPB]
and sonicated briefly. All samples were heat inactivated at
948C for 4 min and stored at 2208C.
Cultured cells. Cultures were rinsed once with PBS and then
incubated in 200 ml of LB for exactly 1 min. The LB was
then transferred to an eppendorf containing 50 ml of 5 SDS-
sample buffer [312.5 mM Tris pH 6.8, 10% SDS, 50% glycerol,
250 mM DTT, PI cocktail (1:500) and BPB] and represents the
soluble protein pool. The cells were rinsed once with PBS,
scraped into 200 ml of LB and then solubilized by the addition
of 50 ml 5 SDS sample buffer. The insoluble protein fraction
was briefly sonicated and both fractions were heat inactivated at
948C for 4 min prior to storage at 2208C.
Western blot
Samples were thawed and heated to 948C for 1 min immedi-
ately prior to loading on 3%–12% gradient SDS–PAGE
gels. Western blot was performed as described (54).
Isoelectric focusing
Frozen muscle biopsy sections were separated into soluble and
insoluble fractions as described earlier. The insoluble fila-
ments were washed once in 1 ml of LB and re-centrifuged
at 15 000 g for 10 min at 48C. Both insoluble and soluble
protein fractions were resuspended in rehydration solution
[2% Triton-X 100, 8 M urea, 2% IPG buffer pH 4–7
(Amersham Biosciences), 36 mM DTT, PI cocktail (1 :500),
BPB], sonicated and solubilized for 20–30 min on ice. To
determine equal loading of patient and control samples, 5 ml
aliquots were separated by SDS–PAGE and western blotted
for sarcomeric actin (5C5 Sigma antibody). Protein samples
were used to hydrate 13 cm immobiline dry strips (pH 4–7,
Amersham Biosciences) overnight at RT. The strips were
focused using a Multiphor IEF unit (Amersham Biosciences)
for a total of 21 000 V/h. Focused strips were incubated in
SDS equilibration buffer (50 mM Tris–Cl pH 8.8, 6 M urea,
30% glycerol, 2% SDS, 10 mM DTT and BPB) with shaking
for 15 min and separated in the second dimension using 9%
acrylamide slab gels. The isoelectric point (pI ) for proteins
was calculated using the pI analysis tool available on the
website http://www.expasy.org/.
Human Molecular Genetics, 2004, Vol. 13, No. 16 1741
Native gel electrophoresis
Transfected NIH3T3 fibroblasts (one 6-well) were scraped
into PBS and pelleted at 300 g for 3 min. Residual PBS
was aspirated, and the cell pellet was resuspended in 35 ml
‘G-actin’ buffer (2 mM Tris pH 8.0, 0.2 mM CaCl2, 0.2 mM
ATP, 0.5 mM phenyl methyl sulfonyl fluoride. The suspension
was frozen on dry ice and thawed in the fingertips three
times, taking care to ‘just thaw’ the samples. The samples
were incubated in ice for 20 min and then spun at 15 000 g
for 5 min at 48C. The supernatant was transferred to a fresh
tube, and combined with an equal volume of loading buffer
(100 mM Tris pH 8.8, 20% glycerol, BPB). 10 ml aliquots
were separated using a 5–12% non-denaturing gradient gel
(375 mM Tris pH 8.8) in Tris–glycine electrophoresis buffer
(25 mM Tris, 192 mM glycine, pH 8.3) with cooling to
168C. Prior to transfer, the gel was incubated in tris–glycine
buffer containing 0.1% SDS for 15 min with agitation.
Proteins were then transferred to PVDF membrane using
Towbin’s transfer buffer (25 mM Tris, 192 mM glycine, 20%
methanol, pH 8.3) at 35 V for 16 h, with recirculating water
cooled to 168C.
ACKNOWLEDGEMENTS
We would like to thank Dr Lesley C. Ades, Dr Susan Arbuckle
and Dr Claire Cooke-Yarborough (Children’s Hospital at
Westmead, NSW, Australia), Dr Joseph Dezordi (Townsville
Hospital, QLD, Australia), Dr Christine Oley (Royal
Children’s Hospital Brisbane, QLD, Australia) and Dr David
Hutchinson (Auckland Hospital, New Zealand) for referral
of patients and patient material. This work was funded by
the National Health and Medical Research Council
(NHMRC #139039) Australia (2001–2005). B.I. and A.D.
are supported by Australian Postgraduate Award (APA)
scholarships.
REFERENCES
1. Wallgren-Pettersson, C., Pelin, K., Hilpela, P., Donner, K., Porfirio, B.,
Graziano, C., Swoboda, K.J., Fardeau, M., Urtizberea, J.A., Muntoni, F.
et al. (1999) Clinical and genetic heterogeneity in autosomal recessive
nemaline myopathy. Neuromuscul. Disord., 9, 564–572.
2. Pelin, K., Hilpela, P., Donner, K., Sewry, C., Akkari, P.A., Wilton, S.D.,
Wattanasirichaigoon, D., Bang, M.L., Centner, T., Hanefeld, F. et al.
(1999) Mutations in the nebulin gene associated with autosomal recessive
nemaline myopathy. Proc. Natl Acad. Sci. USA, 96, 2305–2310.
3. Sewry, C.A., Brown, S.C., Pelin, K., Jungbluth, H., Wallgren-Pettersson, C.,
Labeit, S., Manzur, A. and Muntoni, F. (2001) Abnormalities in the
expression of nebulin in chromosome-2 linked nemaline myopathy.
Neuromuscul. Disord., 11, 146–153.
4. Wallgren-Pettersson, C., Donner, K., Sewry, C., Bijlsma, E.,
Lammens, M., Bushby, K., Giovannucci, U.M., Lapi, E., Odent, S.,
Akcoren, Z. et al. (2002) Mutations in the nebulin gene can cause severe
congenital nemaline myopathy. Neuromuscul. Disord., 12, 674–679.
5. Ilkovski, B., Cooper, S.T., Nowak, K., Ryan, M.M., Yang, N., Schnell, C.,
Durling, H.J., Roddick, L.G., Wilkinson, I., Kornberg, A.J. et al. (2001)
Nemaline myopathy caused by mutations in the muscle alpha-skeletal-
actin gene. Am. J. Hum. Genet., 68, 1333–1343.
6. Sparrow, J.C., Nowak, K.J., Durling, H.J., Beggs, A.H., Wallgren-
Pettersson, C., Romero, N., Nonaka, I. and Laing, N.G. (2003) Muscle
disease caused by mutations in the skeletal muscle alpha-actin gene
(ACTA1). Neuromuscul. Disord. 13, 519–531.
7. Agrawal, P.B., Strickland, C.D., Midgett, C., Morales, A., Newburger, D.,
Poulos, M.H., Tomczak, K.K., Ryan, M.M., Iannaccone, S.T., Crawford,
T.O. et al. (2004) Heterogeneity of nemaline myopathy cases with skeletal
muscle a-actin gene mutations. Ann Neurol., 56, 86–96.
8. Laing, N.G., Wilton, S.D., Akkari, P.A., Dorosz, S., Boundy, K.,
Kneebone, C., Blumbergs, P., White, S., Watkins, H., Love, D.R. et al.
(1995) A mutation in the alpha tropomyosin gene TPM3 associated with
autosomal dominant nemaline myopathyNEM1.Nat. Genet., 10, 249–231.
9. Tan, P., Briner, J., Boltshauser, E., Davis, M.R., Wilton, S.D., North, K.,
Wallgren-Pettersson, C. andLaing, N.G. (1999)Homozygosity for a nonsense
mutation in the alpha-tropomyosin slow gene TPM3 in a patient with severe
infantile nemaline myopathy. Neuromuscul. Disord., 9, 573–579.
10. Wattanasirichaigoon, D., Swoboda, K.J., Takada, F., Tong, H.Q., Lip, V.,
Iannaccone, S.T., Wallgren-Pettersson, C., Laing, N.G. and Beggs, A.H.
(2002) Mutations in the slow muscle alpha-tropomyosin gene, TPM3, a
rare cause of nemaline myopathy. Neurology, 59, 613–617.
11. Donner, K., Ollikainen, M., Ridanpaa, M., Christen, H.J., Goebel, H.H.,
De Visser, M., Pelin, K. and Wallgren-Pettersson, C. (2002) Mutations in
the beta-tropomyosin (TPM2 ) gene—a rare cause of nemaline myopathy.
Neuromuscul. Disord., 12, 151–158.
12. Johnston, J.J., Kelley, R.I., Crawford, T.O., Morton, D.H., Agarwala, R.,
Koch, T., Schaffer, A.A., Francomano, C.A. and Biesecker, L.G. (2000) A
novel nemaline myopathy in the Amish caused by a mutation in troponin
T1. Am. J. Hum. Genet., 67, 814–821.
13. Nowak, K.J., Wattanasirichaigoon, D., Goebel, H.H., Wilce, M., Pelin, K.,
Donner, K., Jacob, R.L., Hubner, C., Oexle, K., Anderson, J.R. et al.
(1999) Mutations in the skeletal muscle alpha-actin gene in patients with
actin myopathy and nemaline myopathy. Nat. Genet., 23, 208–212.
14. Romero, N.B., Barois, A., Leroy, J.-P., Oddy, A., Durling, H., Fardeau, M.
and Laing, N. (2003) Homozygous nonsence mutation of the ACTA1
gene-clinical phenotype and muscle pathology. Abs. Neuromuscul.
Disord., 13, 616.
15. Crawford, K., Flick, R., Close, L., Shelly, D., Paul, R., Bove, K.,
Kumar, A. and Lessard, J. (2002) Mice lacking skeletal muscle actin
show reduced muscle strength and growth deficits and die during
the neonatal period. Mol. Cell. Biol., 22, 5887–5896.
16. Okamoto, H., Hiromi, Y., Ishikawa, E., Yamada, T., Isoda, K.,
Maekawa, H. and Hotta, Y. (1986) Molecular characterisation of
mutant actin genes which induce heat-shock proteins in Drosophila
flight muscles. EMBO J., 5(3), 589–596.
17. Drummond, D.R., Hennessey, E.S. and Sparrow, J.C. (1991)
Characterisation of missense mutations in the Act88F gene in
Drosophila melanogaster. Mol. Gen. Genet., 226, 70–80.
18. Wertman, K.F., Drubin, D.G. and Botstein, D. (1992) Systematic
mutational analysis of the yeast ACT1 gene. Genetics, 132, 337–350.
19. Sparrow, J.C., Drummond, D.R., Hennessey, E.S., Clayton, J.D. and
Lindegaard, F.B. (1992) Drosophila actin mutants and the study of
myofibrillar assembly. Sympos. Soc. Expt. Biol. 46, 111–129.
20. Thompson, T.G., Chan, Y.M., Hack, A.A., Brosius, M., Rajala, M.,
Lidov, H.G., McNally, E.M., Watkins, S. and Kunkel, L.M. (2000)
Filamin 2 (FLN2): a muscle-specific sarcoglycan interacting protein.
J. Cell Biol., 148, 115–126.
21. van der Ven, P.F., Obermann, W.M., Lemke, B., Gautel, M., Weber, K.
and Furst, D.O. (2000) Characterization of muscle filamin isoforms
suggests a possible role of gamma-filamin/ABP-L in sarcomeric Z-disc
formation. Cell Motil. Cytoskeleton, 45, 149–162.
22. Maruyama, K. and Ebashi, S. (1965) Alpha-actinin, a new structural
protein from striated muscle. II. Action on actin. J. Biochem. (Tokyo), 58,
13–19.
23. Blanchard, A., Ohanian, V. and Critchley, D. (1989) The structure and
function of alpha-actinin. J. Muscle Res. Cell Motil., 10, 280–289.
24. Salmikangas, P., Mykkanen, O.M., Gronholm, M., Heiska, L., Kere, J. and
Carpen, O. (1999) Myotilin, a novel sarcomeric protein with two Ig-like
domains, is encoded by a candidate gene for limb-girdle muscular
dystrophy. Hum. Mol. Genet., 8, 1329–1336.
25. Pollock, M. and Atkinson, B.G. (1985) The intermediate filament protein
desmin in cardiac and skeletal muscle from normal and dystrophic (BIO
14.6) hamsters. Can. J. Biochem. Cell Biol., 63, 430–438.
26. Kashiwada, K., Nishida, W., Hayashi, K., Ozawa, K., Yamanaka, Y.,
Saga, H., Yamashita, T., Tohyama, M., Shimada, S., Sato, K. and
Sobue, K. (1997) Coordinate expression of alpha-tropomyosin and
caldesmon isoforms in association with phenotypic modulation of smooth
muscle cells. J Biol. Chem., 272, 15396–15404.
1742 Human Molecular Genetics, 2004, Vol. 13, No. 16
27. Ruiz-Opazo, N. and Nadal-Ginard, B. (1987) Alpha-tropomyosin gene
organization. Alternative splicing of duplicated isotype-specific exons
accounts for the production of smooth and striated muscle isoforms.
J. Biol. Chem., 262, 4755–4765.
28. Goodwin, L.O., Lees-Miller, J.P., Leonard, M.A., Cheley, S.B. and
Helfman, D.M. (1991) Four fibroblast tropomyosin isoforms are expressed
from the rat alpha-tropomyosin gene via alternative RNA splicing and the
use of two promoters. J. Biol. Chem., 266, 8408–8415.
29. Perry, S.V. (2001) Vertebrate tropomyosin: distribution, properties and
function. J. Muscle Res. Cell Motil., 22, 5–49.
30. Corbett, M.A., Akkari, P.A., Domazetovska, A., Cooper, S.T.,
North, K.N., Laing, N.G., Gunning, P.W. and Hardeman, E.C. A mutation
in a-tropomyosinslow alters tropomyosin dimer preference in nemaline
myopathy. Ann. Neurol., in press.
31. Donner, K., Pelin, K., Sandbacka, M., Ahola, H.V., Lehtokari, L. and
Wallgren-Pettersson, C. (2003) Characterisation of nebulin isoforms in
different types of skeletal muscle. Abst. Neuromuscul. Disord., 13, 616.
32. Clement, S., Chaponnier, C. and Gabbiani, G. (1999) A subpopulation of
cardiomyocytes expressing alpha-skeletal actin is identified by a specific
polyclonal antibody. Circ. Res., 85, e51–e58.
33. Goebel, H.H., Anderson, J.R., Hubner, C., Oexle, K. and Warlo, I. (1997)
Congenital myopathy with excess of thin myofilaments. Neuromuscul.
Disord., 7, 160–168.
34. Weeks, D.A., Nixon, R.R., Kaimaktchiev, V. and Mierau, G.W. (2003)
Intranuclear rod myopathy, a rare and morphologically striking variant of
nemaline rod myopathy. Ultrastruct. Pathol., 27, 151–154.
35. Wada, A., Fukuda, M., Mishima, M. and Nishida, E. (1998) Nuclear
export of actin: a novel mechanism regulating the subcellular localization
of a major cytoskeletal protein. EMBO J., 17, 1635–1641.
36. Cooper, S.T., Maxwell, A.L., Ghoddusi, M., Hardeman, E.C.,
Alexander, I.E., Allen, D.G. and North, K.N. (2004) C2C12 co-culture
on a fibroblast substratum enables sustained survival of contractile,
highly differentiated myotubes with peripheral nuclei and adult fast
myosin expression. Cell Motil. Cytoskeleton., 58, 200–11.
37. Shafiq, S.A., Dubowitz, V., Peterson, H.D. and Milhorat, A.T. (1967)
Nemaline myopathy: report of a fatal case, with histochemical and
electron microscopic studies. Brain, 90, 817–828.
38. Dubowitz, V. (1985) Muscle Biopsy: A Practical Approach. Balliere
Tindall, London.
39. Ryan, M.M., Ilkovski, B., Strickland, C.D., Schnell, C., Sanoudou, D.,
Midgett, C., Houston, R., Muirhead, D., Dennett, X., Shield, L.K. et al.
(2003) Clinical course correlates poorly with muscle pathology in
nemaline myopathy. Neurology, 60, 665–673.
40. Jockusch, B.M., Veldman, H., Griffiths, G.W., van Oost, B.A. and
Jennekens, F.G. (1980) Immunofluorescence microscopy of a myopathy.
a-Actinin is a major constituent of nemaline rods. Expt. Cell Res., 127,
409–420.
41. Wallgren-Pettersson, C., Jasani, B., Newman, G.R., Morris, G.E.,
Jones, S., Singhrao, S., Clarke, A., Virtanen, I., Holmberg, C. and
Rapola, J. (1995) Alpha-actinin in nemaline bodies in congenital
nemaline myopathy: immunological confirmation by light and electron
microscopy. Neuromuscul. Disord., 5, 93–104.
42. Schroder, R., Reimann, J., Salmikangas, P., Clemen, C.S., Hayashi, Y.K.,
Nonaka, I., Arahata, K. and Carpen, O. (2003) Beyond LGMD1A:
myotilin is a component of central core lesions and nemaline rods.
Neuromuscul. Disord., 13, 451–455.
43. Muller-Hocker, J., Schafer, S., Mendel, B., Lochmuller, H. and
Pongratz, D. (2000) Nemaline cardiomyopathy in a young adult: an
ultraimmunohistochemical study and review of the literature.
Ultrastruct. Pathol., 24, 407–416.
44. van der Ven, P.F., Jap, P.H., ter Laak, H.J., Nonaka, I., Barth, P.G.,
Sengers, R.C., Stadhouders, A.M. and Ramaekers, F.C. (1995)
Immunophenotyping of congenital myopathies: disorganization of
sarcomeric, cytoskeletal and extracellular matrix proteins. J Neurol. Sci.,
129, 199–213.
45. Hiromi, Y. and. Hotta, Y. (1985) Actin gene mutations in Drosophila:
heat shock activation in the indirect flight muscles. EMBO J., 4,
1681–1687.
46. Kabsch, W., Mannherz, H.G., Suck, D., Pai, E.F. and Holmes, K.C. (1990)
Atomic structure of the actin: DNase I complex Nature, 347, 37–44
[see comments].
47. Chen, X. and Rubenstein, P.A. (1995) A mutation in an ATP-binding loop
of Saccharomyces cerevisiae actin (S14A) causes a temperature-sensitive
phenotype in vivo and in vitro. J. Biol. Chem., 270, 11 406–11 414.
48. Schuler, H., Korenbaum, E., Schutt, C.E., Lindberg, U. and Karlsson, R.
(1999) Mutational analysis of the Ser14 and Asp157 in the nucleotide-
binding site of beta-actin. Eur. J. Biochem., 265, 210–220.
49. Minamide, L.S., Striegl, A.M., Boyle, J.A., Meberg, P.J. and
Bamburg, J.R. (2000) Neurodegenerative stimuli induce persistent
ADF/cofilin-actin rods that disrupt distal neurite function. Nat. Cell Biol.,
2, 628–636.
50. Bamburg, J.R. and Wiggan, O.P. (2002) ADF/cofilin and actin dynamics
in disease. Trends Cell Biol., 12, 598–605.
51. Marston, S., Mirza, M., Abdulrazzak, H. and Sewry, C. (2004) Functional
characterisation of a mutant actin (Met132Val) from a patient with
nemaline myopathy. Neuromuscul. Disord., 14, 167–174.
52. Costa, C.F., Rommelaere, H., Waterschoot, D., Sethi, K.K., Nowak, K.J.,
Laing, N.G., Ampe, C. and Machesky, L.M. (2004) Myopathy mutations
in a-skeletal muscle actin causes a variety of molecular defects. J. Cell
Sci., in press.
53. Lyubimova, A., Bershadsky, A.D. and Ben Ze’ev, A. (1999)
Autoregulation of actin synthesis requires the 30-UTR of actin mRNA
and protects cells from actin overproduction. J. Cell Biochem., 76,
1–12.
54. Cooper, S.T., Lo, H.P. and North, K.N. (2003) Single section western blot:
improving the molecular diagnosis of the muscular dystrophies.
Neurology, 61, 93–97.
Human Molecular Genetics, 2004, Vol. 13, No. 16 1743
